Media coverage about Amgen (NASDAQ:AMGN) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Amgen earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 46.135764181299 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have effected Accern’s analysis:
AMGN has been the topic of several research analyst reports. BMO Capital Markets restated a “market perform” rating and issued a $198.00 price target on shares of Amgen in a research report on Thursday, October 26th. Mizuho restated a “buy” rating and issued a $198.00 price target (up from $183.00) on shares of Amgen in a research report on Thursday, September 28th. Zacks Investment Research lowered shares of Amgen from a “buy” rating to a “hold” rating in a research report on Monday, October 16th. BidaskClub upgraded shares of Amgen from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 2nd. Finally, Morgan Stanley restated an “overweight” rating and issued a $196.00 price target (up from $189.00) on shares of Amgen in a research report on Friday, October 6th. Fifteen analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Amgen currently has a consensus rating of “Hold” and a consensus price target of $190.15.
Amgen (AMGN) traded down $0.42 during trading hours on Thursday, hitting $187.59. 3,083,573 shares of the stock were exchanged, compared to its average volume of 2,720,000. The company has a market cap of $136,170.00, a P/E ratio of 16.95, a price-to-earnings-growth ratio of 2.71 and a beta of 1.36. Amgen has a one year low of $150.38 and a one year high of $191.10. The company has a quick ratio of 5.72, a current ratio of 6.07 and a debt-to-equity ratio of 1.05.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The company had revenue of $5.77 billion during the quarter, compared to the consensus estimate of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The firm’s revenue for the quarter was down .7% compared to the same quarter last year. During the same period last year, the firm earned $3.02 EPS. equities research analysts predict that Amgen will post 12.71 earnings per share for the current fiscal year.
Amgen declared that its board has approved a share repurchase program on Wednesday, October 25th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s board believes its shares are undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be issued a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.81%. This is an increase from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date is Wednesday, February 14th. Amgen’s dividend payout ratio (DPR) is presently 41.55%.
In related news, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $171.58, for a total transaction of $261,659.50. Following the transaction, the executive vice president now directly owns 57,631 shares of the company’s stock, valued at $9,888,326.98. The disclosure for this sale can be found here. Insiders have sold a total of 8,575 shares of company stock valued at $1,508,836 over the last ninety days. 0.19% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/18/amgen-amgn-earning-somewhat-positive-news-coverage-accern-reports.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.